Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a perioperative Phase 2, open-label, non-randomized, single-cohort study in patients
with urothelial carcinoma of the bladder who cannot receive or refuse to receive
cisplatin-based chemotherapy.